Novartis wins U.S. approval for targeted cancer drug combination
FRANKFURT — A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumors that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumor agnostic. The Food and Drug Administration early on Thursday granted accelerated approval […]
Novartis wins U.S. approval for targeted cancer drug combination
FRANKFURT — A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumors that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumor agnostic. The Food and Drug Administration early on Thursday granted accelerated approval […]